Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

被引:0
|
作者
Jos Jonkers
Ralph Meuwissen
Hanneke van der Gulden
Hans Peterse
Martin van der Valk
Anton Berns
机构
[1] Netherlands Cancer Institute,Division of Molecular Genetics and Centre of Biomedical Genetics
[2] Netherlands Cancer Institute,Department of Pathology
来源
Nature Genetics | 2001年 / 29卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Inheritance of one defective BRCA2 allele predisposes humans to breast cancer. To establish a mouse model for BRCA2-associated breast cancer, we generated mouse conditional mutants with BRCA2 and/or p53 inactivated in various epithelial tissues, including mammary-gland epithelium. Although no tumors arose in mice carrying conditional Brca2 alleles, mammary and skin tumors developed frequently in females carrying conditional Brca2 and Trp53 alleles. The presence of one wildtype Brca2 allele resulted in a markedly delayed tumor formation; loss of the wildtype Brca2 allele occurred in a subset of these tumors. Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer.
引用
收藏
页码:418 / 425
页数:7
相关论文
共 50 条
  • [31] BRCA1 carries tumor suppressor activity distinct from that of p53 and p21
    Voahangy Randrianarison
    Didier Marot
    Nicolas Foray
    Jeannine Cabannes
    Vincent Méret
    Elisabeth Connault
    Natacha Vitrat
    Paule Opolon
    Michel Perricaudet
    Jean Feunteun
    Cancer Gene Therapy, 2001, 8 : 759 - 770
  • [32] BRCA1 carries tumor suppressor activity distinct from that of p53 and p21
    Randrianarison, V
    Marot, D
    Foray, N
    Cabannes, J
    Méret, V
    Connault, E
    Vitrat, N
    Opolon, P
    Perricaudet, M
    Feunteun, J
    CANCER GENE THERAPY, 2001, 8 (10) : 759 - 770
  • [33] p53 tumor suppressor gene therapy for cancer
    Roth, JA
    Swisher, SG
    Meyn, RE
    ONCOLOGY-NEW YORK, 1999, 13 (10): : 148 - 154
  • [34] p53 tumor suppressor gene therapy for cancer
    Nielsen, LL
    Maneval, DC
    CANCER GENE THERAPY, 1998, 5 (01) : 52 - 63
  • [35] Germline BRCA2 and somatic P53alterations in male breast cancer
    B Csokay
    N Udvarhelyi
    E Olah
    Breast Cancer Research, 2 (Suppl 1)
  • [36] Tumor suppressor p53 is required to modulate BRCA1 expression
    Arizti, P
    Fang, L
    Park, I
    Yin, YX
    Solomon, E
    Ouchi, T
    Aaronson, SA
    Lee, SW
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (20) : 7450 - 7459
  • [37] Analysis of a novel malignant gastric cancer mouse model harboring loss of tumor suppressor gene p53
    Ohtsuka, Junko
    Ezawa, Issai
    Abe, Ryo
    Oshima, Masanobu
    Ohki, Rieko
    CANCER SCIENCE, 2018, 109 : 222 - 222
  • [38] p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations
    Elisa Sensi
    Mariella Tancredi
    Paolo Aretini
    Giovanna Cipollini
    A. Giuseppe Naccarato
    Paolo Viacava
    Generoso Bevilacqua
    Maria A. Caligo
    Breast Cancer Research and Treatment, 2003, 82 : 1 - 9
  • [39] TUMOR-SUPPRESSOR P53 MUTATIONS AND BREAST-CANCER - A CRITICAL ANALYSIS
    OZBUN, MA
    BUTEL, JS
    ADVANCES IN CANCER RESEARCH, VOL 66, 1995, 66 : 71 - 141
  • [40] P53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations
    Sensi, E
    Tancredi, M
    Aretini, P
    Cipollini, G
    Naccarato, AG
    Viacava, P
    Bevilacqua, G
    Caligo, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (01) : 1 - 9